Therapy of spondylarthropathy in inflammatory bowel disease.

Article Details

Citation

Copy to clipboard

Generini S, Fiori G, Matucci Cerinic M

Therapy of spondylarthropathy in inflammatory bowel disease.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.

PubMed ID

12463455 [ View in PubMed

]

Abstract

Musculoskeletal manifestations represent the most common extra-intestinal complication of inflammatory bowel diseases (IBD) and are usually included in the clinical spectrum of the spondyloarthropathies (SpA). Although control of intestinal inflammation often ameliorates articular symptoms, sometimes arthropathy is independent of the gut disease course and may require the same therapeutic options which apply to primary SpA diseases, but with caution so as not aggravate the IBD. At the moment, salicylates (sulphasalazine and mesalazine) and selective COX-2 inhibitors (which are preferable to traditional NSAIDs although they cannot be assumed to be safe for the gastrointestinal tract) are the first choice treatment. Several immunosuppressive and biological agents including methotrexate, thalidomide and TNFalpha antagonists have efficacy for both articular and intestinal inflammation and are currently in use for the induction of remission and for maintenance in more severe cases. New combination therapies and novel biologically-driven treatments, targeted to specific pathophysiological processes, might offer less toxicity and the potential for better treatment outcomes.

DrugBank Data that Cites this Article

Drugs

Sulfasalazine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Aminosalicylic acid	Prostaglandin G/H synthase 2	Protein	Humans	Unknown	Inhibitor	Details
Mesalazine	Prostaglandin G/H synthase 2	Protein	Humans	Yes	Inhibitor	Details
Sulfasalazine	Prostaglandin G/H synthase 2	Protein	Humans	Yes	Inhibitor	Details